Clinical Trials Logo

Recurrent Glioblastoma clinical trials

View clinical trials related to Recurrent Glioblastoma.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05663125 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas

Start date: December 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to investigate the safety and efficacy of Laser Interstitial Thermal Therapy (LITT) combined with postoperative early use of temozolomide in treating recurrent glioblastomas.

NCT ID: NCT05324501 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

MAGIC-G1
Start date: October 19, 2022
Phase: Phase 1
Study type: Interventional

A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

NCT ID: NCT05191784 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Start date: January 26, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.

NCT ID: NCT04826393 Active, not recruiting - Glioblastoma Clinical Trials

ASP8374 + Cemiplimab in Recurrent Glioma

Start date: March 9, 2022
Phase: Phase 1
Study type: Interventional

This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma. The study will be conducted in two parts, the first portion of the study will be to establish the highest dose of ASP8374 that can be given safely with cemiplimab and will be used as the recommended dose of ASP8374 in combination with cemiplimab for the second portion of the study. The second portion of the study will be to compare the effect of having ASP8374 in combination with cemiplimab prior to surgery. The names of the study drugs involved in this study are: - ASP8374 - Cemiplimab

NCT ID: NCT04671459 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine

TaRRGET
Start date: December 26, 2020
Phase: Phase 2
Study type: Interventional

All patients will receive TTFields therapy and additionally Stereotactic Radiosurgery . Radiosurgery will be based on MRI and FET-PET or MRI alone. Addition of FET-PET will be preferred option.

NCT ID: NCT04479241 Active, not recruiting - Glioblastoma Clinical Trials

LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma

Start date: October 21, 2020
Phase: Phase 2
Study type: Interventional

This Phase 2 single arm trial in patients with rGBM will characterize the efficacy, safety, tolerability and initial efficacy of lerapolturev intratumoral infusion followed by intravenous pembrolizumab 14 to 28 days later, and every 3 weeks, thereafter.

NCT ID: NCT04440358 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

Start date: October 13, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.

NCT ID: NCT04417088 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

Start date: November 6, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.

NCT ID: NCT04406272 Active, not recruiting - Glioblastoma Clinical Trials

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.

NCT ID: NCT04221503 Active, not recruiting - Glioblastoma Clinical Trials

Niraparib/TTFields in GBM

Start date: December 30, 2019
Phase: Phase 2
Study type: Interventional

Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).